Drugs / INT2104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06539338 | Sep 2024 → Jul 2026 overdue | B-cell non-Hodgkin lymphoma, precursor lymphoblastic lymphoma/leukemia | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT2104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06539338 ↗ |
| Route | Intravenous | “following intravenous (IV) administration” NCT06539338 ↗ |